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Abstract
The purpose of the present investigation is to analyze the in vivo genotoxicity dose–
response data of ethylene oxide (EO) and the applicability of the derived point-of-
departure (PoD) values when estimating permitted daily exposure (PDE) values. A total
of 40 data sets were identified from the literature, and benchmark dose analyses were
conducted using PROAST software to identify a PoD value. Studies employing the
inhalation route of exposure and assessing gene or chromosomal mutations and chro-
mosomal damage in various tissues were considered the most relevant for assessing
risk from EO, since these effects are likely to contribute to adverse health conse-
quences in exposed individuals. The PoD estimates were screened for precision and
the values were divided by data-derived adjustment factors. For gene mutations, the
lowest PDE was 285 parts per trillion (ppt) based on the induction of lacI mutations in
the testes of mice following 48 weeks of exposure to EO. The corresponding lowest
PDE value for chromosomal mutations was 1,175 ppt for heritable translocations in
mice following 8.5 weeks of EO exposure. The lowest PDE for chromosomal aberra-
tions was 238 ppt in the mouse peripheral blood lymphocytes following 48 weeks of
inhalation exposure. The diverse dose–response data for EO-induced genotoxicity
enabled the derivation of PoDs for various endpoints, tissues, and species and identi-
fied 238 ppt as the lowest PDE in this retrospective analysis.
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1 | INTRODUCTION
Genotoxicity is routinely evaluated during safety assessments of syn-
thetic and natural substances. Excitement over the promise of simple
and inexpensive genotoxicity tests to predict cancer outcomes in
rodents fueled the development of a multitude of short-term tests
starting in the 1970s. The primary focus of testing since that time has
been to answer the qualitative question of whether a substance has
genotoxic potential (Gollapudi et al., 2013; Gollapudi, 2017). Conse-
quently, more attention has been paid in the field to maximize the
dose levels evaluated in these assays in order to optimize the ability
to detect an induced response. The analysis of dose–response and the
identification of no-effect-levels attracted relatively little consider-
ation. In recent years, however, there has been growing interest in
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using genotoxicity data to inform not only cancer mode of action but
also to quantitatively assess risk from exposure to genotoxic agents
(Pottenger et al., 2007; Pottenger and Gollapudi, 2009; 2010;
Gollapudi et al., 2013; Johnson et al., 2014; MacGregor et al., 2015a,
2015b; Dearfield et al., 2017; Heflich et al., 2020; Klapacz and
Gollapudi, 2020; White et al., 2020). The precedent came from Müller
and Gocke (2009) who used mutagenicity data to derive permitted
exposure levels of a human pharmaceutical contaminated with the
mutagen ethyl methane sulfonate, which received acceptance from
regulatory authorities (e.g., European Medicines Agency
[EMEA], 2008). Recently, Luijten et al. (2020) applied quantitative
dose–response analyses to the in vivo micronucleus (MN) test results
to identify a point-of-departure (PoD) value to calculate permitted
daily exposure (PDE) limits for benzene. As a result, the field of
genetic toxicology is in the midst of a transformation, toward the
vision of its founders who saw the potential of using genotoxicity data
for risk assessments and for the development of practical exposure
limits (International Commission for Protection Against Environmental
Mutagens and Carcinogens [ICPEMC], 1980).
The applicability of the available genotoxicity data to risk assess-
ment is an area of ongoing inquiry in the field. There are several sub-
stances whose published genotoxicity data are potentially useful for
quantitative dose–response analyses to inform risk assessment. Ethyl-
ene oxide (EO; CAS Nr. 75-21-8) is one such chemical. It is a simple
epoxide with a molecular formula C2H4O. It is extensively used in the
chemical industry as an intermediate in the manufacture of other
chemicals; it is also used as a sterilizing agent for medical equipment
and as a fumigant for spices. There is strong evidence for tumorigenic-
ity of EO following chronic inhalation exposures in animals but less
than conclusive evidence in humans (U.S. Environmental Protection
Agency [U.S. EPA], 2016; Texas Commission on Environmental Qual-
ity [TCEQ], 2020). In the absence of experimental evidence to the
contrary, mutagenicity induced by EO (as reviewed below) was
hypothesized as the default mode of action for its tumorigenicity (U.S.
EPA, 2016; Jinot et al., 2018).
EO is produced metabolically in the liver from endogenously avail-
able ethylene (Ehrenberg et al., 1977; Törnqvist et al., 1989; Filser
et al., 1992). EO in vivo, therefore, derives both from continuous
endogenous production and from episodic exposures to exogenous
sources including background EO in ambient air. Endogenous levels in
human populations with negligible exogenous exposure to EO have
been reported to range from 0.13 to 6.9 parts per billion, when
expressed in terms of exogenous exposures of EO (Kirman and
Hays, 2017). EO is a DNA-reactive SN2 alkylating agent that reacts
with macromolecules such as proteins and DNA (Li et al., 1992). Its
DNA adduct profile, assessed from in vitro studies with naked DNA,
reveals hydroxyethyl (HE) adducts formed primarily at the N7 position
of guanine (N7-HEG; 81%), the N3 position of adenine (N3-HEA; 10%),
and the N1 position of adenine (N1-HEA; 7%) (Li et al., 1992). N6 posi-
tion of adenine (N6-HEA), N3 position of cytosine (N3-HEC; which
converts to uracil [N3-HEU]), and N3 position of thymine (N3-HET)
adducts are also produced in small amounts (Li et al., 1992). Further-
more, earlier in vitro work reported formation of a small amount of O6
position of guanine (O6-HEG; 0.4%) (Segerbäck, 1990). EO also has the
potential to react with the DNA phosphate backbone (Ehrenberg and
Hussain, 1981; Dellarco et al., 1990; Agurell et al., 1991).
The N7-HEG adduct is by far the most abundant, but it is not
considered mutagenic. N7-HEG is chemically unstable and spontane-
ously depurinated, leaving behind abasic sites that are rapidly repaired
(Boysen et al., 2009). Although N7-HEG is not itself a pro-mutagenic
adduct (Philippin et al., 2014), its depurinations form abasic sites that
could result in mutations if present during DNA replication. However,
inhalation exposures of rats to 100 ppm (ppm) EO for 4 weeks (6 hr
per day/5 days per week) did not reveal an increase in abasic sites
over the exposure period (Rusyn et al., 2005). Although production by
EO of its minor DNA adducts, some of which (e.g., O6-HEG) may be
more mutagenic, is proportional to its production of the major adduct
(Li et al., 1992), this proportionality can vary across tissues and doses.
Nonetheless, within a tissue, N7-HEG is a useful surrogate for quanti-
fying overall EO-induced DNA damage.
Numerous studies have investigated the genotoxicity of
EO. Although it is a relatively weak genotoxicant, the number of posi-
tive tests has fostered a contrary belief. The published genetic activity
profile for EO shows that the average lowest-effective-exposure con-
centration required to give a positive result in the in vitro assays was
between 1.0 and 100 μg/ml (Waters et al., 1999). EO blood levels of
this magnitude require inhalation exposures greater than 150 ppm for
4 hr in mice (Brown et al., 1996). Illustrative of this, in pSP189 shuttle
vector replicated in human Ad293 cells in vitro, exposure concentra-
tions up to 2 mM induced only the non-pro-mutagenic N7-HEG
adducts with no increase in the frequency of mutations (Tompkins
et al., 2009). Increased mutations were observed only when the concen-
trations were increased to 10–30 mM, concomitant with the appear-
ance of pro-mutagenic N1-HEA, O6-HEG, and N3-HEU DNA adducts.
High acute doses of EO administered via intraperitoneal (IP) or
intravenous (IV) injection or in drinking water have been shown to
increase the frequencies of MN or chromosomal aberrations in mice
and rats (Strekalova et al., 1971; Applegren et al., 1978; Conan
et al., 1979; Jenssen and Ramel, 1980; Farooqi et al., 1993; Lorenti
Garcia et al., 2001). However, these dosing methods are not relevant
to human exposure scenarios. In inhalation studies, a route of expo-
sure relevant to humans, no increases in chromosomal or MN aberra-
tions were found in peripheral blood/splenic lymphocytes from rats
exposed to EO at concentrations of 50–450 ppm for 1 or 3 days
(6 hr/day) (Kligerman et al., 1983) or 50–200 ppm for 4 weeks
(5 days/week, 6 hr/day) (van Sittert et al., 2000; Lorenti Garcia
et al., 2001). Preston and Abernethy (1993) exposed rats for 1, 2, 3, or
4 weeks (6 hr/day, 5 days/week) to 150 ppm EO by inhalation and
found no increase in the frequency of chromosomal aberrations in
peripheral blood lymphocytes at any sampling time. In contrast, inha-
lation exposure of EO was reported to induce chromosomal aberra-
tions in mice and increase frequency of MN or aberrations in both
mice and rats. Ribeiro et al. (1987) reported that exposures of mice to
200–600 ppm EO by inhalation for 2 weeks induced chromosomal
aberrations in bone marrow cells, whereas Vergnes and Pritts (1994)
found significant increases in bone marrow MN in mice and rats fol-
lowing 4 weeks of inhalation exposure to 200 ppm EO (6 hr/day,
5 days/week). Donner et al. (2010) exposed mice to 0, 25, 50, 100, or
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200 ppm EO by inhalation (6 hr/day, 5 days/week, up to 48 weeks)
with sacrifice and found aberrations at intervals of 6, 12, 24, and
48 weeks. There were no statistically significant increases in aberra-
tion frequencies at any exposure concentration at the 6-week sacri-
fice. Only the two highest concentrations showed significant
increases in total aberration frequencies at 12 weeks. At 24 weeks,
increases in aberrations were seen at the three highest doses while all
exposure concentrations showed significant increases in aberrations
at the 48-week sacrifice.
EO has also been evaluated for the induction of mutations in
endogenous and reporter genes such as the Hprt, K-Ras, lacI, and cII in
mice and rats (Sisk et al., 1997; Walker et al., 1997; 2000; Tates
et al., 1999; van Sittert et al., 2000; Recio et al., 2004; Parsons
et al., 2013; Manjanatha et al., 2017); both positive and negative results
were reported depending on the target gene, exposure concentration,
and duration of exposure. EO has also been investigated for the induc-
tion of germ cell mutations in mice (Generoso et al., 1980; 1986;
1990). Results from the above studies are summarized in conjunction
with the benchmark dose (BMD) modeling results in Section 3.
The purpose of the present investigation is to analyze the publicly
available in vivo genotoxicity dose–response data on EO from experi-
mental mammalian models to identify a PoD and to explore the appli-
cability of the PoD to calculate PDE levels to adequately protect
exposed populations from adverse health outcomes resulting from
mutagenic effects. in vitro genotoxicity data were not considered in
this investigation since methodologies for in-vitro-to-in-vivo extrapo-
lation of dose metrics and detoxification processes are not fully devel-
oped at this time. It is envisioned that the PDE value for genotoxicity
is considered along with PDE values for other toxicity endpoints to
determine the most sensitive endpoint to adequately protect humans
against all adverse outcomes.
2 | MATERIALS AND METHODS
The criteria for study inclusion and BMD analysis, as well as the selec-
tion of factors for extrapolation from animal to human, were determined
before the BMD analysis was conducted. The methods are described in
this section and discussed in greater detail in Section 4. The EPA's con-
vention for terminology is used to report the results. BMD is used
generically to refer to the BMD approach. In the specific cases of char-
acterizing model results, BMD refers to central estimates and BMDL
refers to the corresponding lower 95% confidence limit of the BMD.
2.1 | Overall approach for inclusion criteria and
consideration of study quality
Studies that reported in vivo positive genetic toxicity for EO were
identified from a literature search and the U.S. EPA (2016) recent
evaluation of EO inhalation carcinogenicity. Studies were screened for
reporting statistically significant responses and employing at least
three dose groups (including control dose) for dose–response analysis.
The endpoints selected for evaluation included the induction of gene
mutations, chromosomal mutations, and chromosomal aberrations
(including MN). Studies conducted using cancer tissues, DNA-adducts,
and sister chromatid exchanges and those employing non-standard
parameters were excluded in these analyses. Data reported only in
graphical format were also not included in the analysis. When a study
reported multiple data sets, a number was assigned to each one
(Table 1). One of the studies reporting chromosomal aberrations
included gaps in the calculation of total aberrations (Ribeiro
et al., 1987); however, total aberrations were recalculated by exclud-
ing the gaps for analysis. Ribeiro et al. (1987) also analyzed chromo-
somal aberrations in diakinesis/Metaphase 1 of mouse spermatocytes
following EO exposure; these data, however, were not included in the
analyses since not all types of events recorded as aberrations were
considered to be treatment related (e.g., univalents) (Gollapudi
et al., 1981).
It was the intent of this manuscript to include as many studies as
possible for BMD analysis that were reported in the U.S. EPA (2016)
assessment as well as those published more recently. Therefore, BMD
analysis was applied to all studies meeting the minimum requirements
described above irrespective of exposure route or study quality. How-
ever, for the next step of deriving candidate PDE values for inhalation
exposures, inhalation studies evaluating mutagenicity (i.e., chromo-
somal aberrations, chromosomal mutations, and gene mutations) and
reporting the variability of the data (e.g., SD) were considered to be
the most relevant experimental data (see Section 3 for further
discussion). For purposes of comparison only (i.e., not considered
candidate values) and consistent with our goal of transparent inclu-
siveness, PDE values were also calculated for inhalation studies that
did not report variability by using a data-derived factor to account
for variability (described in detail in Section 2 on PDE derivation). In
the final selection of the PDE value, focused attention was given to
evaluating the relative quality of the inhalation studies that resulted
in the lowest PDE values. At this final step, duration of exposure,
group size, exposure levels tested, dose–response pattern of effect,
and experimental design were evaluated, as discussed in detail in
Section 3.
Several data sets reported mean response values but did not pro-
vide a measure of variance in terms of SD or SE that is necessary for
BMD analysis. These studies were not considered to be of adequate
quality for quantitative dose response analysis for risk assessment
purposes. However, for purposes of comparison, these data sets were
modeled in PROAST without variance, as the response of one animal
for each dose group. Consequently, the BMDL is artificially elevated
(less conservative) because of not having variance information. As
described in greater detail in Section 4, the estimated BMDL50 values
were divided by a data-derived factor of five for these datasets.
An error in the published data was discovered during the evalua-
tion of heritable translocation data from Generoso et al. (1990). Based
on a review of Rhomberg et al. (1990) that summarized Generoso
et al. (1990) data, it became apparent that the data reported in Gener-
oso et al. (1990) in their Table 2 for (SEC × C57BL)F1 female stock is
the same as combined data for both T-stock and (SEC × C57BL)F1.
For this reason, (SEC × C57BL)F1 data from Rhomberg et al. (1990)
were modeled instead.
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TABLE 1 List of ethylene oxide (EO) studies included for benchmark dose (BMD) analyses
Study
Data set
identifier Species—strain Route Effect Tissue Endpoint
Exposure
concentration Frequency and duration
Applegren
et al. (1978)
1 Mouse—NMRI IV Cytogenetic BM MN 0, 50, 100, 150, 200,
and 300 mg/kg
1X/d, 2 days
2 Rat—Sprague
Dawley
IV Cytogenetic BM MN 0, 100, and 150 mg/
kg
1X/d, 2 days
Donner
et al. (2010)
1 Mouse—B6C3F1 IH Cytogenetic PBL CA-RT 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 12 weeks
2 Mouse—B6C3F1 IH Cytogenetic PBL CA-RT 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 24 weeks
3 Mouse—B6C3F1 IH Cytogenetic PBL CA-RT 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 day/week; 48 weeks
4 Mouse—B6C3F1 IH Cytogenetic PBL CA-TA 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 day/week; 12 weeks
5 Mouse—B6C3F1 IH Cytogenetic PBL CA-TA 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 day/week; 24 weeks
6 Mouse—B6C3F1 IH Cytogenetic PBL CA-TA 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 48 weeks
7 Mouse—B6C3F1 IH Cytogenetic S CA-RT 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 12 weeks
8 Mouse—B6C3F1 IH Cytogenetic S CA-RT 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 24 weeks
9 Mouse—B6C3F1 IH Cytogenetic S CA-RT 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 48 weeks
Farooqi et al.
(1993)
1 Mouse—Swiss
albino
IP Cytogenetic BM MN 0, 0.68, 1.36, 2.72,
and 3.40 mmol/kg
1X
Lorenti Garcia
et al. (2001)
1 Rat—Lewis IP Cytogenetic SP MN 0, 50, and 100 mg/kg 1X
2 Rat—Lewis IP Cytogenetic BM MN 0, 50, and 100 mg/kg 1X
Generoso
et al. (1980)
1 Mouse—T-stock IP Mutation GE HTL 0, 30, and 60 mg kg–
1 day–1
5X/week; 5 weeks
Generoso
et al. (1986)
1 Mouse—(C3H
× 101)F1
IH Mutation GE DL 0, 300, 400, and
500 ppm
6 hr/day, 4 days (expr. time
6.5–7.5 days)
2 Mouse—
(C3H × 101)
F1
IH Mutation GE DL 0, 300, 400, 500 ppm 6 hr/day, 4 d (expr. time
4.5–5.5 days)
Generoso
et al. (1990)
1 Mouse—
(C3H × 101)
F1
IH Mutation GE DL 0, 165, 204, 250, and
300 ppm
8.5 weeks; 6 hr/day, 5 days/week
for 6 weeks, then daily for
2.5 weeks
2 Mouse—
(C3H × 101)
F1
IH Mutation GE DL 0, 165, 204, 250, and
300 ppm
8.5 weeks; 6 hr/day, 5 days/week
for 6 weeks, then daily for
2.5 weeks
3 Mouse—
(C3H × 101)
F1
IH Mutation GE HTL 0, 165, 204, 250, and
300 ppm
8.5 weeks; 6 hr/day, 5 days/week
for 6 weeks, then daily for
2.5 weeks
4 Mouse—
(C3H × 101)
F1
IH Mutation GE HTL 0, 165, 204, 250, and
300 ppm
8.5 weeks; 6 hr/day, 5 days/week
for 6 weeks, then daily for
2.5 weeks
Jenssen and
Ramel
(1980)
1 Mouse—CBA IP Cytogenetic BM MN 0, 50, 100, 125, 150,
and 175 mg/kg
1X
Lynch
et al. (1984)
1 Monkey—
Macaca
fascicularis
IH Cytogenetic PBL CA 0, 50, and 100 ppm 7 hr/day, 5 days/week; 2 years
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2.2 | BMD analysis
The BMD analysis using PROAST v. 67.0 (Dutch National Institute
for Public Health and the Environment [RIVM], 2019) was con-
ducted on the data sets to identify PoD values for EO-induced gen-
otoxicity. PROAST was chosen instead of the U.S. EPA BMD
software to be consistent with previous BMD analyses of the
genetic toxicology data (e.g., Gollapudi et al. 2013; Johnson
et al. 2014). The critical effect size (CES; or benchmark response,
BMR) of 50% was used as described in greater detail in Section 4.
The data sets in their original exposure units were modeled in
PROAST for continuous response data.
Some data sets included zero values in their response metrics for
one or more dose levels, and those values are not amenable to model-
ing in PROAST, where responses are modeled in logarithmic scale. A
conventional approach of using surrogate values to address those
instances was used by replacing the zero value in the numerator with
an incidence rate of 1 for the affected metric. For reported zero SD or
SE values at a given dose, they were also replaced with surrogate vari-
ance values by assuming that the coefficient of variation of response
at that dose is similar to that of the next highest dose having nonzero
variance value. The surrogate variance value is calculated as the
reported mean response at the given dose multiplied by the coeffi-
cient of variation of the next nonzero variance dose.
TABLE 1 (Continued)
Study
Data set
identifier Species—strain Route Effect Tissue Endpoint
Exposure
concentration Frequency and duration
Manjanatha
et al. (2017)
1 Mouse—Big Blue
B6C3F1
IH Mutation LU cII 0, 10, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 4 weeks
2 Mouse—Big Blue
B6C3F1
IH Mutation LU cII 0, 100, and 200 ppm 6 hr/day, 5 days/week; 8 weeks
3 Mouse—Big Blue
B6C3F1
IH Mutation LU cII 0, 100, and 200 ppm 6 hr/day, 5 days/week; 12 weeks
Parsons
et al. (2013)
1 Mouse—Big Blue
B6C3F1
IH Mutation LU K-ras 0, 10, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 4 weeks
2 Mouse—Big Blue
B6C3F1
IH Mutation LU K-ras 0, 10, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 4 weeks
Recio
et al. (2004)
1 Mouse—B6C3F1
lacI transg.
IH Mutation BM lacI 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 48 weeks
2 Mouse—B6C3F1
lacI transg.
IH Mutation TE lacI 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 48 weeks
3 Mouse—B6C3F1
lacI transg.
IH Mutation TE lacI 0, 25, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 24 weeks
Ribeiro
et al. (1987)
1 Mouse—Swiss
Webster
IH Cytogenetic BM CA 0, 200, 400, and
600 ppm
6 hr, 1 day
2 Mouse—Swiss
Webster
IH Cytogenetic BM CA 0, 200, and 400 ppm 6 hr/day, 5 days/week; 2 weeks
(total 12 days)
Tates et al.
(1999)
1 Rat—Lewis IP Mutation SL Hprt 0, 20, 40, 80 mg/kg 1X (expr. time 32 days)
2 Rat—Lewis IP Mutation SL Hprt 0, 10, 20, 40, and
80 mg/kg
1X (expr. time 35 days)
3 Rat—Lewis DW Mutation SL Hprt 0, 2, 5, and 10 mM 30 days (expr. time 35 days)
4 Rat—Lewis DW Mutation SL Hprt 0, 2, 5, and 10 mM 30 days (expr. time 41 days)
5 Rat—Lewis IH Mutation SL Hprt 0, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 4 weeks
(expr. time 21 days)
van Sittert
et al. (2000)
1 Rat—Lewis IH Mutation SL Hprt 0, 50, 100, and
200 ppm
6 hr/days, 5 day/week; 4 weeks
Walker
et al. (1997)
1 Mouse—B6C3F1
lacI transg.
IH Mutation SL Hprt 0, 50, 100, and
200 ppm
6 hr/day, 5 days/week; 4 weeks
Note: Inhalation studies are the key studies most relevant for derivation of an inhalation permitted daily exposure (PDE) value. Studies using different
routes of exposure are italicized and presented for completeness.
Abbreviations: BM, bone marrow; CA, chromosomal aberration; CA-RT, chromosomal aberration-reciprocal translocation; CA-TA, chromosomal aberration-
total aberration; cII, cII mutation; DL, dominant lethal mutation; DW, drinking water; GE, male germ cells; Hprt, hprt mutation; HTL, heritable translocation;
IH, inhalation; IP, intraperitoneal; IV, intravenous; K-ras, K-ras mutation; lacI, lacI mutation; LU, lung cells; MN, micronucelus formation; PBL, peripheral
blood lymphocytes; S, spermatogonia cells; SL, splenic lymphocytes; SP, splenocytes; TE, testes.
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Results of dominant lethal mutation studies reported zero or neg-
ative response values since the response metrics of percent dominant
lethality is defined as the difference of fetal deaths between treat-
ment and the control group (1—average living treated/average living
controls) (Generoso et al., 1986). By definition, the percent dominant
lethals is always zero for the control group, and the result can be neg-
ative for the treated group if average living is greater than in controls.
Since PROAST does not allow entry of zero or negative response
values, the results are expressed as one minus the percent dominant
lethals for the modeling analysis.
The data sets were not further transformed for the BMD analysis
in PROAST. PROAST evaluated the data sets using four models (expo-
nential, hill, inverse exponential, and lognormal) and provided model
estimates for BMD (BMD central estimate), 90% confidence interval
around the central estimate as BMDL (lower 95% confidence limit),
BMDU (upper 95% confidence limit), and model average results. The
best fit model is selected based on having the lowest Akaike informa-
tion criterion (AIC) value and visual examination of model fit. In
instances when visual examination of the fitted model showed a bio-
logically unreasonable fit (e.g., nonmonotonic, very steep S-curve), the
result of that model was excluded from consideration. A model result
is also excluded from consideration where the BMDL values appear
unreliable, such as when the BMDU/BMDL ratio is >100, the BMDL
value is estimated as greater than the BMDU, BMDL is zero, or
BMDU is infinity.
2.3 | Dose conversion to continuous inhalation
concentrations
The dose metric used in all the BMD analyses presented here is the
experimental exposure concentration, rather than the continuous
exposure concentration that is relevant to human health risk assess-
ment. Because inhalation studies on EO reviewed were conducted
over 6 or 7 hr/day and 5 days/week (whole-body exposure), all the
estimated BMD50 and BMDL50 values were then converted to contin-
uous inhalation (CI) concentration (CIBMD and CIBMDL50) over
24 hr/day and 7 days/week. For inhalation, the approach used in
U.S. EPA (2016) for EO was followed. The BMD values in the original
units were multiplied by hours of test exposure per 24 hr and by
5 days test exposure per 7 days to obtain continuous daily exposure
values.
Although EO exposures by routes other than inhalation were not
used to determine PDEs, quantitative analyses of dose responses in
these studies were made for comparative purposes. For IP or IV
injections only, the equivalent human CI exposures are obtained fol-
lowing the approach used in U.S. EPA (1996); the BMD values in the
original units were multiplied by 70 kg20 m−3 day−1, with an addi-
tional factor of 5 days test exposure/7 days for repeat dose expo-
sures, and the result was divided by 0.75 to account for the fraction
of EO in air being retained during inhalation in humans (Brugnone
et al., 1986).
2.4 | Derivation of PDE levels via inhalation
For the derivation of candidate PDE for inhalation exposure, the inha-
lation studies reporting some measure of variability (e.g., SD or SE)
evaluating mutagenicity (i.e., chromosomal aberration, chromosomal
mutations, and gene mutations) were considered the most relevant
experimental data for human risk assessment. However, PDEs were
also derived for studies that did not meet these criteria, with addi-
tional adjustments as described below and in greater detail in
Section 4.
PDE=CIBMDL50 ppmð Þ=F1×F2×F3×F4,
where PDE = permitted daily exposure; CIBMDL50 = CI 50%
response BMD lower 95% confidence limit; F1 = a data-derived inter-
species factor of 3.16 was applied instead of the standard 10, consis-
tent with U.S. EPA (2016) use of 1 for the toxicokinetic interspecies
subfactor; F2 = a factor of 10 to account for inter-individual variabil-
ity; F3 = A variable factor to account for studies of short-term expo-
sure; F3 = 1 for studies that last at least one-half lifetime (1 year for
rodents or rabbits; 7 years for cats, dogs, and monkeys); F3 = 1 for
reproductive studies in which the whole period of organogenesis is
covered; F3 = 2 for a 6-month study in rodents or a 3.5-year study in
nonrodents; F3 = 5 for a 3-month study in rodents or a 2-year study
in nonrodents; F3 = 10 for studies of a shorter duration; and F4 = a
factor of 10 was used for severity of the effect induced by gen-
otoxicity/mutagenicity.
In the final step of selecting the PDE from among the lowest can-
didate PDEs, the following factors were considered: duration of treat-
ment, group size (minimum of 5), BMDU:BMDL ratio, number and
range of exposure levels tested, dose–response pattern, and experi-
mental design.
3 | RESULTS
3.1 | Data used for BMD analysis
Forty data sets were identified for dose–response analyses (Table 1).
Except for one study in monkeys, all other studies were conducted in
either rats or mice. All these studies were conducted by treating males
except for Farooqi et al. (1993) who used female mice in their study
and Applegren et al. (1978) who did not specify the sex of mice and
rats used in their study. The routes of exposure included IP or IV
injection, drinking water, and inhalation. The primary route of human
exposure to EO is via inhalation, and as such, laboratory studies using
inhalation exposure are considered the most relevant for human risk
assessment. Data from studies using IP, IV, or drinking water adminis-
tration were nevertheless included in the dose–response analysis for
comparative purposes only (Table 2). The duration of treatments
ranged from a single administration to exposures up to 2 years. Data
derived from studies conducted with longer treatment durations are
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considered the most appropriate for chronic risk assessment as com-
pared to acute or shorter-term exposures. Both somatic and germ
cells were investigated for genotoxicity across these studies.
The 40 data sets cover a wide range of genotoxicity endpoints,
including MN formation, chromosomal aberrations, reciprocal translo-
cations, gene mutations in the endogenous (Hprt locus) and transgenic
reporter (lacI and cII) genes, dominant lethal mutations, and heritable
translocations. Distinguishing between “mutagenicity” and “gen-
otoxicity” is critical when using these data for risk assessment pur-
poses. The term “genotoxicity” describes a continuum of events that
may or may not lead to mutations. Mutagenicity, on the other hand,
refers to changes in the DNA nucleotide sequence of the genome,
transmissible from one cell to the daughter cells or from one genera-
tion to the other. Mutations differ from all other endpoints in the gen-
otoxicity continuum in that they are the apical effects and as such are
not repairable by the normal cellular defense mechanisms. Although
not all mutations have a phenotypic consequence, the specific gene
mutations evaluated in EO-exposed rats and mice (i.e., Hprt, lacI, and
cII) are detected by selection-based methodologies, and as such, they
are not silent mutations.
For human health risk assessment purposes, dose–response data
for gene mutations and chromosomal effects that satisfied the quality
criteria listed in Section 2 were considered the most appropriate end-
points. Chromosomal aberrations (including MN formation) were also
considered to be relevant for risk assessment since their incidence has
been shown to correlate to cancer in human biomonitoring studies
(Norppa et al., 2006; Bolognesi et al., 2015). The mutational endpoints
and chromosomal aberrations analyzed in the experimental studies
reviewed in here are good predictors of the type of genetic damage
that can lead to adverse health outcomes.
3.2 | BMD analyses
Results from BMD50 analyses are presented in Table 2. Of the 40 data
sets evaluated, 28 data sets successfully estimated BMD values.
Nearly all data sets have low (<10) BMDU/BMDL ratios, suggesting a
high level of precision of the BMD50 estimates. Higher BMDU/BMDL
ratios of 31 and 134 (Donner et al., 2010) (chromosomal aberration in
peripheral blood lymphocytes), and 47 and 80 (Recio et al., 2004) (lacI
mutations in testes) indicate that the BMD estimates from these data
are not as precise as the other data sets. The results with unreason-
ably large uncertainty, defined here as having a BMDU/BMDL ratio
>100 (i.e., ratio of 134 from Donner et al. (2010)) were excluded from
PDE derivation. For several data sets that did not report SD or SE,
adjusted BMDL estimates were also listed in the table. Figure 1 shows
sample PROAST modeling outputs using Donner et al. (2010) data set
6, Generoso et al. (1990) data set 4, and Recio et al. (2004) data set 2.
3.3 | Identification of PoD for the derivation of
candidate PDE
As stated earlier, inhalation studies are considered the most relevant
for human risk assessment on EO, and they are the basis for candidate
PDE derivation. There are six data sets for gene mutations (cII, lacI,
and Hprt) with model fit and acceptable BMDU/BMDL ratios (Table 3)
and six acceptable data sets each for chromosomal mutations (domi-
nant lethals and heritable translocations; Table 4) and chromosomal
aberrations (Table 5). Candidate PDE values were not derived from
studies that reported MN formation since the routes of exposure
were IP or IV. The following sections provide detailed descriptions of
F IGURE 1 Examples of benchmark dose (BMD) analysis results adapted from PROAST outputs (see Appendix S1 for actual model output
that provide greater details). Shown in the figure are the best-fit models for the lowest permitted daily exposure (PDE) derivation for
(a) chromosomal aberration (Donner et al. (2010) data set 6), (b) chromosomal mutation (Generoso et al. (1990) data set 4), and (c) gene mutations
(Recio et al. (2004) data set 1). Name of the fitted model is shown above each figure. Triangle symbols and error bars are the geometic mean and
confidence interval of the reported data. Solid curves are the modeled relationships between exposure and response. The controls are plotted at
an arbitrary (but low) location on the log-dose scale because log of zero is undefined; for that reason the model curve at the lower end is
represented as a dashed line. Horizontal and vertical dashed lines indicate exposure associated with 50% response, but they may be difficult to
see in (a) and (b) because they are very close to the axes. BMD50 is the 50% response benchmark dose central estimate, BMDL50 is the lower
95% confidence limit, and BMDU50 is the upper 95% confidence limit
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weight of evidence, including consideration of study quality and
dose–response pattern for the lowest candidate PDE values.
3.3.1 | Mutations
The three categories of genotoxicity endpoints analyzed here are
gene mutations, chromosome mutations, and chromosome aberra-
tions. As indicated above, mutations are nonrepairable changes in
DNA sequences that are heritable and change genetic information
content. Gene and chromosome mutations completely fulfill this defi-
nition, the latter referring to chromosome level changes measured in
germ cells. Chromosome aberrations, however, are somewhat differ-
ent in that, even though being non-repairable events that change
genetic content, the most common kind of aberrations scored are of
the chromatid type and therefore, strictly speaking, not heritable
because they are cell lethal. However, some chromosome aberrations
are heritable, fulfilling all criteria for the strict definition of mutations.
For example, the Donner et al. (2010) study included here measured
reciprocal translocations, in addition to total chromosomal aberra-
tions. Reciprocal translocations are heritable. Since chromosome aber-
rations capture mechanisms that underlie all mutations, they are
included in the analyses presented here.
3.3.2 | Gene mutations
For gene mutations, the lowest CIBMDL value was 0.09 ppm based
on the induction of gene mutations in testes (seminiferous tubules) of
mice following 48 weeks of inhalation exposure to EO (Table 3; (Recio
et al., 2004). The study design was considered robust for deriving a
PDE because of the chronic duration of exposure, because of the
inclusion of 5 exposure levels including control, and because the
exposure levels ranged from 25 to 200 ppm, a range below that caus-
ing metabolic saturation in mice. However, the BMDL value is a con-
servative PoD based on the dose–response pattern. The target gene
analyzed in this study was a bacterial gene (lacI) incorporated into the
genome of a mouse. The PDE value based on this CIBMDL was
285 parts per trillion (ppt). The data used for the BMD analysis was
extracted from Table 4 of Recio et al. The lacI mutant frequencies
(× 10−5; mean ± SD) were 3.6 ± 3.2, 6.2 ± 2.2, 7.7 ± 3.4, 8.5 ± 6.5,
and 4.2 ± 2.7 at exposure concentrations of 0, 25, 50, 100, and
200 ppm EO, respectively. The mutant frequency values for 25, 50,
and 100, but not for 200 ppm, were statistically different from 0 ppm.
PROAST initially did not find a significant dose–response with the
inclusion of the 200-ppm dose. The BMD analysis for this data set
was successful after excluding the 200-ppm dose. A closer examina-
tion of the data reveals that the response observed was marginally
dose related, and the precision of the BMD estimates are at the bor-
derline of acceptability with a BMDU to BMDL ratio of 80. Further-
more, the spectrum of lacI mutations in EO-exposed mice in the
above study was not significantly different from the lacI background
mutations. It is also noteworthy that, in the same study, the
mutational spectrum for EO-exposed bone marrow cells differed sig-
nificantly from the background with a significant increase in the
expected AT to TA transversions—a molecular signature of EO-
induced mutations. Additionally, there is a high level of variation at
each dose, along with overlapping levels of variation between each
dose and the vehicle control. Due to this high variation, it is inconclu-
sive whether there is a dose response or not. Thus, although a PDE
value was calculated from this data set, it needs to be pointed out that
the value derived from this data set should be viewed with a greater
degree of caution given (a) the lack of molecular signature, (b) the high
BMDU to BMDL ratio, and (c) the wide variation in the data.
Measurements by Parsons et al. (2013) of K-ras Codon
12 GGT ! GAT mutations in lung cells of male mice exposed to
10, 50, 100, or 200 ppm EO by inhalation for 4 weeks resulted in the
next lowest CIBMDL value of 0.19 ppm. Measurements for Codon
12 GGT ! GTT mutations resulted in a CIBMDL value of 0.29 ppm.
This data set did not meet criteria for derivation of a PDE because no
response variance was reported.
A CIBMDL value of 4 ppm was calculated for Hprt mutations in
splenic lymphocytes of mice exposed to EO by inhalation for 4 weeks
(Walker et al., 1997). The BMD analysis used the following mean (±SE)
of observed mutant frequencies from Walker et al. (1997): 2.2 (0.3),
3.8 (0.5), 6.8 (0.9), and 14.1 (1.1) at exposure concentrations of 0, 50,
100, and 200 ppm, respectively. The BMD estimate for this data set
has an acceptable degree of precision as assessed from the BMDU:
BMDL ratio of 2.6. The target gene in this study (Hprt) is an endoge-
nous gene that responds to small basepair insertions, deletions, and
substitutions in DNA, as well as large (mega basepair) deletions (Stout
and Caskey, 1985; Lippert et al., 1995). The PDE calculated using this
data set was 1,203 ppt.
van Sittert et al. (2000) also investigated the induction of Hprt
mutations in splenic lymphocytes of rats after 4 weeks of inhalation
exposure to EO. Although exposure levels and duration are the same
as the ones observed by Walker et al. (1997), the increases in mutant
frequencies observed by van Sittert et al. (2000) were only marginal,
with mean (SD) values of 4.41 (1.45), 3.21 (1.06), 5.49 (2.10), and 6.41
(2.33) at 0, 50, 100, and 200 ppm, respectively. Only the mutant fre-
quency observed at the 200-ppm level was significantly different from
the control value. The CIBMDL value for this data was 9 ppm with a
corresponding PDE value of 2,790 ppt. Thus, the PDE value based on
the rat data is 2.3-fold higher than the corresponding value resulting
from the analysis of data obtained in the mouse using a similar experi-
mental design.
Recio et al. (2004) observed significant increase in lacI mutant fre-
quency in the bone marrow of transgenic mice after 48 weeks of
exposure to 100 and 200 ppm (but not to 25 or 50 ppm) EO. No
increases in mutant frequencies were noted at any of the above expo-
sure levels following 12 or 24 weeks of exposure. Manjanatha
et al. (2017), on the other hand, observed significant (<2.5-fold)
increases in cII mutant frequency in the lungs of transgenic mice at
8 and 12 weeks of exposure, but not at 4 weeks. The CIBMDL values
and the corresponding PDE estimates are also listed in Table 3 for
comparative purpose.
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3.3.3 | Chromosomal mutations
Dominant lethal mutations are due to chromosomal aberrations in the
germ cells leading to the death of embryos following fertilization,
while heritable translocations lead to semi-sterility in the progeny of
exposed individuals that carry such events (Table 4). Both these
assays are conducted in the germ cells of males. The effect of EO on
these endpoints was investigated by Generoso and colleagues via
inhalation exposure in two strains of mice (Generoso et al., 1986;
1990). BMD analysis was conducted for the reported data sets; how-
ever, the authors recognized that the responses were reported in
terms of pups (N > 100 and up to 2,068 per dose group), while the
experimental units should have been based on the exposed male sires
(N = 24 per dose group) to account for litter effects. Quantitative
BMD analysis based on pups instead of male sires is not appropriate
for risk assessment purposes because it inflates the sample size. The
lowest CIBMDL value was 3.7 ppm for heritable translocations in
(C3H × 101)F1 mouse strain mated with (SEC × C57Bl)F1 females,
which is followed by the value 7.2 ppm for the same endpoint in the
mating of (C3H × 101)F1 treated males with T-stock female mice. The
corresponding PDE values were 1,175 and 2,287 ppt for the two
female stocks, respectively. For dominant lethal mutations, the
CIBMDL values were in the range of 10–17 ppm depending upon the
strain and exposure levels tested with the corresponding PDE values
ranging from 3,196 to 5,274 ppt.
3.3.4 | Chromosomal aberrations
The endpoints in this category include reciprocal translocations and
total chromosome aberrations evaluated in metaphase cells following
exposure to EO (Table 5).
The lowest CIBMDL for chromosomal aberrations with an accept-
able BMDU to BMDL ratio (i.e., <100) was 0.075 ppm for the periph-
eral blood lymphocytes of B6C3F1 mice exposed by inhalation to EO
for 48 weeks (Donner et al., 2010). The study design is considered
robust for deriving a PDE value because of the chronic exposure dura-
tion, the inclusion of five exposure levels including controls, and the
adequate group size of 6–8. The PDE value after applying the adjust-
ment factors to this CIBMDL estimate is 238 ppt. The dose-related
increase in aberrations was relatively weak, with the highest concen-
tration (200 ppm) inducing less than 1% aberrations. In this study,
there was no effect on aberration incidence at 6 weeks of exposure
to 25, 50, 100, and 200 ppm EO, and the increases observed at
12 and 24 weeks were also weak (<1%). The overall weak response is
likely related to the limited number of chromosomes interrogated for
aberrations (4 pairs of painted chromosomes out of 20 pairs). For
reciprocal translocations reported by Donner et al. (2010), the PDE
values ranged from 1,039 to 4,715 ppt. Unfortunately, the data on
reciprocal translocations in the primary spermatocytes of mice
reported by Donner et al. (2010) did not fit any of the dose–response
models in PROAST, and as such, no BMD values could be calculated
from these data.
In the study by Lynch et al. (1984), chromosomal aberrations in
peripheral blood lymphocytes of monkeys were evaluated following
exposure to EO (50 or 100 ppm) for 2 years. This study could be con-
sidered the most relevant for human exposures based on the relevant
species, the longest chronic exposure duration, and ample group size.
A small but statistically significant increase in aberrant cells was
noticed in this study at both concentrations: 0.6% in the 0-ppm group
versus 2.0 and 3.7% at 50 and 100 ppm EO exposure groups, respec-
tively. The CIBMDL value for this study was 0.3 ppm, and the
corresponding PDE estimate is 909 ppt.
Ribeiro et al. (1987) investigated chromosomal aberrations in the
bone marrow of mice after a single 6-hr exposure to EO at concentra-
tions of 200, 400, and 600 ppm. The incidence of cells with aberra-
tions (after excluding gaps from the reported values) was 0.4, 1.0, 3.0,
and 3.4% at 0, 200, 400, and 600 ppm, respectively. The CIBMDL for
this data set was 4.2 ppm with an estimated PDE of 1,333 ppt.
4 | DISCUSSION
4.1 | In vivo genotoxicity of EO
EO induced gene mutations, chromosomal mutations, and chromo-
somal aberrations in somatic and germ cells of experimental animals
following inhalation exposure—the route of exposure most relevant to
human risk assessment. The positive response in these studies
appears to be dependent upon the concentration and duration of
exposure. Some of the studies employed exposure concentrations
≥300 ppm. In mice, but not in rats, the detoxification of EO is satu-
rated at an exposure concentration of 330 ppm (Brown et al., 1996).
Since these high concentrations have no environmental relevance and
exceeded the kinetically derived maximum dose (KMD), the informa-
tion derived from such studies should be viewed with caution for
human risk assessment, especially if the adverse effects were
observed only at doses exceeding the KMD (Bus, 2017). EO is also a
relatively weak genotoxicant, both in the magnitude of the observed
response and the doses and exposure durations needed to elicit a sig-
nificant response (Recio et al., 2004; Donner et al., 2010).
4.2 | Selection of BMR and extrapolation/
uncertainty factors
As described in Section 2, an a priori approach for BMD analysis was
developed. The rationale behind several of the decisions made for this
EO case study merits further discussion.
The BMD analysis for EO is not intended to identify a threshold
dose level but to identify a PoD dose that induces a predetermined
change in the response rate of the endpoint of interest, which can be
used for risk assessment purposes. Recent analyses have shown that
a CES or BMR in the range of 50% is more appropriate for in vivo
mutagenicity data (Zeller et al., 2017) than the CES of 5% (Hardy
et al., 2017) or 10% (Johnson et al., 2014; MacGregor et al., 2015a,
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2015b). A CES of 50%, or BMR50, was selected for identifying the
PoD using the approaches from Slob (2017) and Zeller et al. (2017).
These two different approaches are based on determining a low but
measurable increase above the background that can supersede the
no-observed-effect level (NOEL) as the most suitable PoD metric for
calculating human exposure limits. Both independent approaches have
been used by the Genetic Toxicology Technical Committee of the
Health and Environmental Sciences Institute (Washington, DC) to
define endpoint-specific CES of 50% for the in vivo MN assay and the
transgenic rodent (TGR) mutation assays. These endpoint-specific
CES ensure that the PoD is precisely derived and biologically relevant
for that endpoint. Note that for these continuous endpoints, a 50%
CES or BMR50 is comparable to a 1.5-fold increase above the back-
ground. An interesting comparison is that many toxicological end-
points, including TGR mutant frequency, have the pairwise testing
significance level set at a twofold increase. Therefore, the NOEL can
be anything below a twofold increase. An additional “severity” factor
of 10 was applied to all BMDL estimates to account for the potential
severity of the effect induced by genotoxicity/mutagenicity. Further
discussion among the scientific community is needed regarding the
appropriateness of this factor for all genotoxicity or mutagenicity end-
points. Studies that did not provide some measure of variability
(e.g., SD or SE) were considered inadequate for PDE derivation but
were included for comparison purposes. The BMDL estimate for stud-
ies that do not report some measure of variability is artificially ele-
vated (less conservative). The BMDL was divided by an adjustment
factor of five based on the ratio of BMD and BMDL values from inha-
lation studies that provided variance data, which showed average
BMD:BMDL ratios as high as 4.9. The BMD:BMDL ratios averaged
4.9 for chromosomal aberrations (5 studies), 1.3 for chromosomal
mutations (2 studies), 2.7 for gene mutations (7 studies), and 3.3 over-
all (14 studies across all endpoints). Thus, an adjustment factor of five
was selected to be conservative (protective).
Candidate PDE values were calculated for inhalation studies using
general guidance from international regulatory agencies. Consistent
with U.S. EPA (2014) guidance on data-derived extrapolation factors,
quantitative data were used to replace default uncertainty factors for
interspecies and intraspecies extrapolation. Data are available for the
toxicokinetic component of the F1 factor to extrapolate from animal
to human. Specifically, no interspecies scaling for rodent-to-human
exposure concentration is needed based on U.S. EPA (2016) compari-
sons of measured EO air: blood partition coefficients in humans, mice,
and rats, which showed partition coefficients in rodents are higher
than in humans (i.e., assuming equivalent exposure concentration is
conservative). This approach is also supported by validated the physi-
ologically based pharmacokinetic (PBPK) model of Fennell and
Brown (2001) that showed blood EO area-under-the-curves with
respect to air concentration are similar for rodents and humans at up
to 200 ppm. Similarly, no monkey-to-human scaling for the Lynch
et al. (1984) data set is needed since monkey pharmacokinetics are
presumed to be more like humans than rodents.
Although studies not using the inhalation route of exposure did
not meet our a priori study criteria for inclusion, a PDE was derived
for these studies for comparison purposes. A data-derived adjustment
factor of 0.75 was applied to account for the fact that 100% of the IP
and IV doses are delivered, whereas only 75% of EO in air is retained
by humans exposed via inhalation (Brugnone et al., 1986).
While the adjustment factors described above were considered
appropriate for the EO analyses presented here, we realize that they
are subject to further debate among the scientific community. This
issue was discussed at length recently by White et al. (2020). One of
the most contentious adjustment factors is the variable factor used
for the duration of the study (see F3 in Section 2). Typically, the dos-
ing regimen in genetic toxicity studies is acute or subacute (28 days)
and often use doses orders of magnitude higher than anticipated
human exposure. Such a dose regimen is consistent with the recom-
mendations of various regulatory agencies and international guide-
lines for testing. The logical question then is whether there is a need
for an uncertainty factor of 10 for a genetic toxicity study conducted
for less than 3 months in rodents. We elected to apply the standard
uncertainty factors for the analyses presented here since this issue is
still unresolved and arguments can be presented for and against the
use of this factor. For example, both Donner et al. (2010) and Recio
et al. (2004) have clearly shown an exposure duration dependent
increase in chromosomal aberrations and gene mutations in mice,
respectively, with Recio et al. observing increases in mutations in the
bone marrow only at 48 weeks but not at 12 or 24 weeks of expo-
sure to EO.
4.3 | Genotoxicity of EO as an endpoint for risk
assessment
The recognition and the emphasis in recent years that genotoxicity
data could and should be used on its own merit for human risk assess-
ment (Gollapudi et al., 2013; Johnson et al., 2014; Heflich et al., 2020;
Klapacz and Gollapudi, 2020) provided the impetus to examine the
available EO dose–response data for the identification of a PoD for
the derivation of a PDE. The in vivo genotoxicity of EO has been
investigated via various routes of exposure. Data from other routes of
exposure were also analyzed and presented in Table 2, for compara-
tive purposes only.
Genotoxicity of EO has been examined in multiple species: mice,
rats, and monkeys. This poses the question of which species is the
most relevant to human risk assessment. Non-human primates are
assumed to be more relevant to humans than rats and mice in terms
of physiology and breathing patterns. Based on the PBPK model of
Fennell and Brown (2001), rats, mice and humans are similar in terms
of internal dosimetry of EO at exposures less than 200 ppm. At expo-
sure levels >200 ppm, rats are more similar to humans than mice in
terms of internal dosimetry of EO, whereas mice diverge from rats
and humans. For the purpose of EO mutagenicity risk assessment,
data from all three species (mice, rats, and monkeys) were considered
equally informative since genotoxicity of EO was evident in these spe-
cies at exposure concentrations around and below 200 ppm. Similarly,
no distinction was made on the strain of mouse used in these
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investigations due to a paucity of data on strain specific EO metabo-
lism and dosimetry. Furthermore, in the analysis reported here, no
remarkable differences in BMD estimates were observed in most
cases when different strains (albeit limited in number) were investi-
gated for the same endpoint (see Table 5).
As discussed previously, data on gene and chromosomal mutations
along with chromosome aberrations were considered the most relevant
for risk assessment. Although multiple tissues/cell types (bone marrow,
peripheral blood lymphocytes, splenic lymphocytes, and germ cells)
were investigated for EO-induced genotoxicity, the effects observed in
all these tissues were considered equally informative since the objec-
tive is to identify a dose level of EO that provides an acceptable level
of protection to the genome of an individual. Such a dose level is also
believed to protect the individual from all the adverse effects mediated
through mutagenicity such as heritable diseases, cancer, and diseases
associated with somatic mosaicism (Heflich et al., 2020).
To identify the lowest PDE values for different endpoints, only
those values derived from data sets reporting a variability metric in
Tables 3–5 were considered. For chromosomal mutations, the
CIBMDL for heritable translocations in (C3H × 101)F1 mice from
8.5 weeks of EO exposures reported by Generoso et al. (1990)
resulted in the lowest PDE value of 1,175 ppt. However, this candi-
date PDE value is not appropriate to use for risk assessment purposes
because the experimental unit of measurement should have been
based on the exposed male sires and not the individual pups. For gene
mutations, the lowest PDE value of 285 ppt is derived from the
CIBMDL for lacI mutations in male germ cells following 48-week
exposure reported by Recio et al. (2004). As discussed before, there
are limitations regarding the data set used to derive this value, includ-
ing the absence of a dose–response and lack of molecular signature
consistent with EO-induced mutagenesis. Furthermore, the analysis
for lacI mutants in the bone marrows of the same mice as those used
for interrogating germ cell mutations (following 48 weeks of exposure
to EO) gave a clear dose response accompanied by a mutational spec-
trum consistent with EO-induced mutagenicity. The PDE value
derived from the bone marrow data was 17,505 ppt. Such a huge dif-
ference in PDE between bone marrow and testes (17,505 ppt versus
285 ppt for testes) is mechanistically unexplainable since germ cells
are considered to be relatively less sensitive to EO-induced mutage-
nicity due to the prolonged G1 phase of the spermatogonial cell cycle,
providing greater opportunity for the repair of induced genetic dam-
age (Donner et al., 2010). Despite the limitations of the germ cell data
from Recio et al. (2004), the corresponding PDE value (i.e., 285 ppt)
was still considered a worst-case scenario for this case study.
Although it would be ideal to verify the germ cell findings of Recio
et al. in an independent study, such a replicate study is unrealistic
given the complexity and expense of this chronic study. The PDE
values (based on CIBMDL) for other studies listed in Tables 3 and 4
for gene and chromosomal mutations ranged from 2,287 to
15,924 ppt. For chromosomal aberrations, the lowest PDE value of
238 ppt was estimated from the data reported in Donner et al. (2010)
for peripheral blood lymphocytes of mice following 48 weeks of expo-
sure to EO (Table 5).
Collectively, the lowest PDE estimates for chromosomal muta-
tions, gene mutations, and chromosomal aberrations were 1,175,
285, and 238 ppt, respectively. While the estimates for gene and
chromosomal mutations were derived from male germ cells, the PDE
value for chromosomal aberrations was derived from somatic cells.
The lowest of the three values (238 ppt derived for chromosomal
aberration in peripheral blood lymphocytes from Donner et al. (2010))
could thus represent the permissible daily exposure to EO based on
the quantitative analysis of the genetic toxicology data on EO for risk
assessment purposes.
The PDE of 238 ppt proposed in this publication is more than
three orders of magnitude higher than the 0.1 ppt established by the
U.S. EPA (2016) and similar to the 240 ppt estimated from
TCEQ (2020) risk values for 1-in-106 (1/M) extra risk. Both agencies
based their risk assessments on the same cohort of sterilizer workers
(Steenland et al., 2003; 2004). The major reason for the >2,000-fold
difference in the 1/M extra risk level is the selection of two quite dif-
ferent statistical models used for low-dose extrapolation. The
U.S. EPA Integrated Risk Information System (2016) applied a
supralinear two-piece linear spline model based on statistical signifi-
cance and a major emphasis on visual fit of different models with cat-
egorical grouped data points. These grouped data were few in number
(5 or 10) and not representative of the much larger (53 and 233) num-
ber of cases that were actually modeled. The supralinear model
implies a very steep increase in extra risk at lower exposures com-
pared to higher exposure levels. In contrast, TCEQ (2020) selected the
standard Cox proportional hazards (Cox PH) model based on the bio-
logical cancer mode of action as the primary basis for informing the
low-dose extrapolation, statistical significance, and consideration of
which model accurately predicts the observed data overall and in the
lower exposure regions. The Cox PH model, also selected by the
European Commission Scientific Committee on Occupational Expo-
sure Limits for EO (SCOEL, 2012), is linear over exposures of interest
(TCEQ, 2020). For additional perspective, the TCEQ cancer risk value
for 1/M extra risk of 240 ppt and the proposed PDE value of 238 are
below mean endogenous equivalent EO exposures of
1,900 ± 1,300 ppt measured in humans (Kirman and Hays, 2017).
4.4 | Concluding remarks
The diverse dose–response data for EO-induced genotoxicity avail-
able from the literature enabled the identification of PoDs for various
endpoints, tissues, and species in this retrospective analysis. Generat-
ing such diverse data prospectively from studies that are compliant
with the Organization for Economic Co-operation and Development
test guidelines, while desirable, is prohibitively expensive and time
consuming.
Several challenges in the BMD analysis were encountered during
this study. Some of the challenges included data quality, experimental
design, and PROAST model evaluation. While some challenges were
addressed with ad hoc solutions, as documented in Section 2, others
involved inherent data quality issue that could not be resolved
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completely. In general, given the maturity of the genotoxicity litera-
ture on EO, the 40 data sets reviewed herein were not designed with
the objective of conducting quantitative BMD analysis for PDE deri-
vation. In some cases, the studies were published more than two
decades ago and do not meet current standards for data quality
(e.g., variance not reported). Our novel approach of carrying out BMD
analysis on each dose response, even those without optimum study
design, provided an additional and very useful method of assessment.
Precision of the BMD through the BMD CI range and certain data sets
showing no dose response at the doses tested enabled enhanced dis-
cussion around those data sets and provided increased focus on and
confidence in the studies used for PDE assessment.
To improve the quality of genotoxicity studies for quantitative
analysis, we identified several important issues. First, studies should
have at least three exposure levels in addition to the control. As Slob
et al. (2005) explained, BMD analysis benefits from a design with
more dose groups. More dose groups (e.g., 3 or 4 treated exposure
levels), each with an adequate number of animals (e.g., ≥5), can better
characterize dose–response relationships and identify the BMD with-
out losing statistical precision. Ideally, these dose levels should be rel-
evant to human exposure levels avoiding excessive toxicity
(e.g., consideration of clinical observations, histopathology, and meta-
bolic saturation). Second, the traditional approach in genotoxicity
studies is to report data with litter as the experimental unit for domi-
nant lethal studies but with individual pups as the experimental unit
for heritable translocations. In the case of the heritable translocation
test, the male sires are the experimental unit (i.e., they were the ones
that were exposed). If their sperm is affected, then the male sire and
not the individual pups in the litter spawned by them should be con-
sidered the experimental unit for quantitative analysis (Piegorsch and
Haseman, 1991). This is consistent with guidance developed by
U.S. EPA (1991) for developmental toxicity risk assessment. Third,
several data sets included zero response such that surrogate values
had to be developed with assumptions the authors consider reason-
able so they could be included in this analysis, but which nevertheless,
are assumptions. Fourth, BMD results should be examined carefully
against the data to determine whether the results are biologically
plausible and consistent with the authors' conclusions. Due to either
inherent data quality, dose spacing, and/or modeling algorithm limita-
tions, some results could be numerically illogical (e.g., lower confi-
dence limit higher than upper confidence limit) or, more critically, not
biologically reasonable, as exemplified by the huge difference in
CIBMDL for lacI mutations between bone marrow (5.5 ppm) and tes-
tes (0.09 ppm). There were also instances where goodness-of-fit sta-
tistics conveyed good model fit to the data, yet visual examination of
the modeled dose–response curve found its shape biologically unrea-
sonable (e.g., sharp-S). Additional quality considerations that could aid
in selecting studies for PDE derivation include characterization of test
material, evidence of monitoring chamber concentrations during
exposure, and detection of an effect in the positive control to demon-
strate technical competence in identifying an induced effect.
As quantitative approaches for the application of genotoxicity
data advance, an issue that merits further discussion is whether to
derive acceptable exposure levels separately for somatic and germ
cells. Some scientists might consider the PDE value for somatic cells
more relevant for protecting against carcinogenic effects in the
exposed population while the PDE for germ cells might be more rele-
vant for protecting future generations. Obviously, the lower of the
two values would afford protection against both adverse outcomes.
However, data from germ cells are seldom available for a vast majority
of substances, precluding the derivation of PDE for germ cells. While
the PDE values derived for somatic and germ cell endpoints are
approximately the same for EO, further analyses with a broader set of
substances are necessary to determine whether the value derived
from the somatic cells is predictive of the PDE for germ cells.
As the field of genetic toxicology moves from qualitative hazard
identification to quantitative risk assessment, it is recommended that
genetic toxicology testing be designed such that high-quality dose–
response data are available for quantitative analysis and the identifica-
tion of PoD values with high levels of precision. The species of choice
and route of exposure for testing should be based on considerations
relevant to humans. In the specific case of EO, there are two chronic
inhalation mutagenicity studies of adequate quality for BMD analysis
that provide converging evidence supporting the lowest PDE of
238 ppt.
ACKNOWLEDGMENTS
The authors thank Drs. Bas Bokkers and Wout Slob of the Dutch
National Institute for Public Health and the Environment (RIVM) for
their patient and enlightening responses to our many PROAST-related
queries.
CONFLICT OF INTEREST
Funding for this work was provided by the American Chemistry Coun-
cil, Ethylene Oxide Task Force, and LyondellBasell. Decisions con-
cerning analysis and conclusion were made solely by the authors. The
opinions of the authors do not necessarily reflect the opinions of the
sponsors.
AUTHOR CONTRIBUTIONS
B. Bhaskar Gollapudi, Abby A. Li, and Richard J. Albertini contributed
equally to the conceptualization of the project. All authors contributed
equally to data analysis, interpretation, and drafting of the manuscript.
ORCID
George E. Johnson https://orcid.org/0000-0001-5643-9942
REFERENCES
Agurell, E., Cederberg, H., Ehrenberg, L., Lindahl-Kiessling, K., Rannug, U.
and Törnqvist, M. (1991) Genotoxic effects of ethylene oxide and pro-
pylene oxide: a comparative study. Mutation Research, 250(1–2),
229–237.
Applegren, L.E., Eneroth, G., Grant, C., Lanström, L.E. and Tenghagen, K.
(1978) Testing of ethylene oxide for mutagenicity using the micronu-
cleus test in mice and rats. Acta Pharmacologica et Toxicologica, 43,
69–67.
Bolognesi, C., Bonassi, S., Knasmueller, S., Fenech, M., Bruzzone, M.,
Lando, C. and Ceppi, M. (2015) Clinical application of micronucleus
GOLLAPUDI ET AL. 17
test in exfoliated buccal cells: a systematic review and metanalysis.
Mutation Research, Reviews in Mutation Research, 766, 20–31.
Boysen, G., Pachkowski, B.F., Nakamura, J. and Swenberg, J.A. (2009) The
formation and biological significance of N7-guanine adducts. Mutation
Research, 678(2), 76–94.
Brown, C.D., Wong, B.A. and Fennell, T.R. (1996) In vivo and in vitro kinet-
ics of ethylene oxide metabolism in rats and mice. Toxicology and
Applied Pharmacology, 136(1), 8–19.
Brugnone, F., Perbellini, L., Faccini, G.B., Pasini, F., Bartolucci, G.B. and
DeRosa, E. (1986) Ethylene oxide exposure: biological monitoring by
analysis of alveolar air and blood. International Archives of Occupational
and Environmental Health, 58, 105–112.
Bus, J.S. (2017) “The dose makes the poison”: key implications for mode of
action (mechanistic) research in a 21st century toxicology paradigm.
Current Opinions in Toxicology, 3, 87–91.
Conan, R.A., Waggy, G.T., Spiegel, M.H. and Berglund, R.L. (1979) Study of
the mutagenic action of ethylene oxide, ethylene glycol, and
2-chloroethanol residues in plastic material sterilized by ethylene
oxide. Annales des Falsifications et De L'Expertise Chimique et
Toxicologique, 72, 141–151.
Dearfield, K.L., Gollapudi, B.B., Bemis, J.C., Benz, R.D., Douglas, G.R.,
Elespuru, R.K., Johnson, G.E., Kirkland, D.J., LeBaron, M.J., Li, A.P.,
Marchetti, F., Pottenger, L.H., Rorije, E., Tanir, J.Y., Thybaud, V., van
Benthem, J., Yauk, C.L., Zeiger, E. and Luijten, M. (2017) Next genera-
tion testing strategy for assessment of genomic damage: a conceptual
framework and considerations. Environmental and Molecular Mutagene-
sis, 58(5), 264–283.
Dellarco, V.L., Generoso, W.M., Sega, G.A., Fowle, J.R. and Jacobson-
Kram, D. (1990) Review of the mutagenicity of ethylene oxide
(Review). Environmental and Molecular Mutagenesis, 16, 85–103.
Donner, E.M., Wong, B.A., James, R.A. and Preston, R.J. (2010) Reciprocal
translocations in somatic and germ cells of mice chronically exposed
by inhalation to ethylene oxide: implications for risk assessment. Muta-
genesis, 25(1), 49–55.
Dutch National Institute for Public Health and the Environment (RIVM)
2019 PROAST. Version 67.0 (menu-driven). Available at: https://
www.rivm.nl/en/proast [Accessed 29th October 2019].
Ehrenberg, L. and Hussain, S. (1981) Genetic toxicity of some important
epoxides (Review). DNA Repair, 86, 1–113.
Ehrenberg, L., Osterman-Golkar, S., Segerbäck, D., Svensson, K. and
Calleman, C.J. (1977) Evaluation of genetic risks of alkylating agents.
III. Alkylation of haemoglobin after metabolic conversion of ethene to
ethene oxide in vivo. Mutation Research, 45(2), 175–184.
European Commission Scientific Committee on Occupational Exposure
Limits (SCOEL). (2012). Recommendation from the Scientific Committee
on Occupational Exposure Limits for ethylene oxide. Available at: https://
ec.europa.eu/social/BlobServlet?docId=7879. [Accessed 16th April
2020].
European Medicines Agency (EMEA). (2008). Studies assessed by the
European Medicines Agency indicate no increased risk of developing
cancer for patients who have taken Viracept contaminated with ethyl
mesilate. Press release. Available at: https://www.ema.europa.eu/en/
news/studies-assessed-european-medicines-agency-indicate-no-
increased-risk-developing-cancer-patients-who. [Accessed 16th April
2020].
Farooqi, Z., Törnqvist, M., Ehrenberg, L. and Natarajan, A.T. (1993) Geno-
toxic effects of ethylene oxide and propylene oxide in mouse bone
marrow cells. Mutation Research, 299, 223–228.
Fennell, T.R. and Brown, C.D. (2001) A physiologically based pharmacoki-
netic model for ethylene oxide in mouse, rat, and human. Toxicology
and Applied Pharmacology, 173, 161–175.
Filser, J.G., Denk, B., Törnqvist, M., Kessler, W. and Ehrenberg, L. (1992)
Pharmacokinetics of ethylene in man; body burden with ethylene
oxide and hydroxyethylation of hemoglobin due to endogenous and
environmental ethylene. Archives of Toxicology, 66, 157–163.
Generoso, W.M., Cain, K.T., Cornett, C.V., Cacheiro, N.L. and Hughes, L.A.
(1990) Concentration–response curves for ethylene-oxide-induced
heritable translocations and dominant lethal mutations. Environmental
and Molecular Mutagenesis, 16(2), 126–131.
Generoso, W.M., Cain, K.T., Hughes, L.A., Sega, G.A., Braden, P.W.,
Gosslee, D.G. and Shelby, M.D. (1986) Ethylene oxide dose and dose-
rate effects in the mouse dominant-lethal test. Environmental Mutagen-
esis, 8(1), 1–7.
Generoso, W.M., Cain, K.T., Krishna, M., Sheu, C.W. and Gryder, R.M.
(1980) Heritable translocation and dominant-lethal mutation induction
with ethylene oxide in mice. Mutation Research, 73(1), 133–142.
Gollapudi, B.B. (2017) An ongoing journey toward a risk-based testing in
genetic toxicology. Current Opinion in Toxicology, 3, 71–74.
Gollapudi, B.B., Johnson, G.E., Hernandez, L.G., Pottenger, L.H.,
Dearfield, K.L., Jeffrey, A.M., Julien, E., Kim, J.H., Lovell, D.P.,
Macgregor, J.T., Moore, M.M., van Benthem, J., White, P.A., Zeiger, E.
and Thybaud, V. (2013) Quantitative approaches for assessing dose–
response relationships in genetic toxicology studies. Environmental and
Molecular Mutagenesis, 54(1), 8–18.
Gollapudi, B.B., Kamra, O.P. and Blecher, S.R. (1981) A search for a genetic
basis for gonosomal univalency in mice. Cytogenetics and Cell Genetics,
29(4), 241–249.
Hardy, A., Benford, D., Halldorsson, T., Jeger, M.J., Knutsen, K.H., More, S.,
Mortensen, A., Naegeli, H., Noteborn, H., Ockleford, C., Ricci, A.,
Rychen, G., Silano, V., Solecki, R., Turck, D., Aerts, M., Bodin, L.,
Davis, A., Edler, L., Gundert-Remy, U., Sand, S., Slob, W., Bottex, B.,
Abrahantes, J.C., Marques, D.C., Kass, G. and Schlatter, J.R. (2017)
Update: use of the benchmark dose approach in risk assessment. EFSA
Journal, 15(1), 4658.
Heflich, R.H., Johnson, G.E., Zeller, A., Marchetti, F., Douglas, G.R., Witt, K.
L., Gollapudi, B.B. and White, P.A. (2020) Mutation as a toxicological
endpoint for regulatory decision-making. Environmental and Molecular
Mutagenesis, 61(1), 34–41.
International Commission for Protection Against Environmental Mutagens
and Carcinogens (ICPEMC). (1980) ICPEMC news no. 2. Environmental
Health Perspectives, 34, 223–225.
Jenssen, D. and Ramel, C. (1980) The micronucleus test is part of a short-
term mutagenicity test program for the prediction of carcinogenicity
evaluated by 143 agents test. Mutation Research, 75, 191–202.
Jinot, J., Fritz, J.M., Vulimiri, S.V. and Keshava, N. (2018) Carcinogenicity
of ethylene oxide: key findings and scientific issues. Toxicology Mecha-
nisms and Methods, 28(5), 386–396.
Johnson, G.E., Soeteman-Hernández, L.G., Gollapudi, B.B., Bodger, O.G.,
Dearfield, K.L., Heflich, R.H., Hixon, J.G., Lovell, D.P., MacGregor, J.T.,
Pottenger, L.H., Thompson, C.M., Abraham, L., Thybaud, V., Tanir, J.Y.,
Zeiger, E., van Benthem, J. and White, P.A. (2014) Derivation of point
of departure (PoD) estimates in genetic toxicology studies and their
potential applications in risk assessment. Environmental and Molecular
Mutagenesis, 55(8), 609–623.
Kirman, C.R. and Hays, S.M. (2017) Derivation of endogenous equivalent
values to support risk assessment and risk management decisions for
an endogenous carcinogen: ethylene oxide. Regulatory Toxicology and
Pharmacology, 91, 165–172.
Klapacz, J. and Gollapudi, B.B. (2020) Considerations for the use of muta-
tion as a regulatory endpoint in risk assessment. Environmental and
Molecular Mutagenesis, 61(1), 84–93.
Kligerman, A.D., Erexson, G.L., Phelps, M.E. and Wilmer, J.L. (1983) Sister-
chromatid exchange induction in peripheral blood lymphocytes of rats
exposed to ethylene oxide by inhalation.Mutation Research, 120, 37–44.
Li, F., Segal, A. and Solomon, J.J. (1992) In vitro reaction of ethylene oxide
with DNA and characterization of DNA adducts. Chemico-Biological
Interactions, 83(1), 35–54.
Lippert, M.J., Nicklas, J.A., Hunter, T.C. and Albertini, R.J. (1995) Pulsed
field analysis of hprt T-cell large deletions: telomeric region breakpoint
spectrum. Mutation Research, 326(1), 51–64.
18 GOLLAPUDI ET AL.
Lorenti Garcia, C., Darroudi, F., Tates, A.D. and Natarajan, A.T. (2001)
Induction and persistence of micronuclei, sister-chromatid exchanges
and chromosomal aberrations in splenocytes and bone-marrow cells of
rats exposed to ethylene oxide. Mutation Research, 492, 59–67.
Luijten, M., Ball, N.S., Dearfield, K.L., Gollapudi, B.B., Johnson, G.E.,
Madia, F., Peel, L., Pfuhler, S., Settivari, R.S., Ter Burg, W., White, P.A.
and van Benthem, J. (2020) Utility of a next generation framework for
assessment of genomic damage: a case study using the industrial
chemical benzene. Environmental and Molecular Mutagenesis, 61(1),
94–113.
Lynch, D.W., Lewis, T.R., Moorman, W.J., Burg, J.R., Gulati, D.K., Kaur, P.
and Sabharwal, P.S. (1984) Sister-chromatid exchanges and chromo-
some aberrations in lymphocytes from monkeys exposed to ethylene
oxide and propylene oxide by inhalation. Toxicology and Applied Phar-
macology, 76(1), 85–95.
MacGregor, J.T., Frötschl, R., White, P.A., Crump, K.S., Eastmond, D.A.,
Fukushima, S., Guérard, M., Hayashi, M., Soeteman-Hernández, L.G.,
Johnson, G.E., Kasamatsu, T., Levy, D.D., Morita, T., Müller, L.,
Schoeny, R., Schuler, M.J. and Thybaud, V. (2015b) IWGT report on
quantitative approaches to genotoxicity risk assessment II. Use of
point-of-departure (PoD) metrics in defining acceptable exposure
limits and assessing human risk. Mutation Research, Genetic Toxicology
and Environmental Mutagenesis, 783, 66–78.
MacGregor, J.T., Frötschl, R., White, P.A., Crump, K.S., Eastmond, D.A.,
Fukushima, S., Guérard, M., Hayashi, M., Soeteman-Hernández, L.G.,
Kasamatsu, T., Levy, D.D., Morita, T., Müller, L., Schoeny, R.,
Schuler, M.J., Thybaud, V. and Johnson, G.E. (2015a) IWGT report on
quantitative approaches to genotoxicity risk assessment I. methods
and metrics for defining exposure-response relationships and points of
departure (PoDs). Mutation Research, Genetic Toxicology and Environ-
mental Mutagenesis, 783, 55–65.
Manjanatha, M.G., Shelton, S.D., Chen, Y., Parsons, B.L., Myers, M.B.,
McKim, K.L., Gollapudi, B.B., Moore, N.P., Haber, L.T., Allen, B. and
Moore, M.M. (2017) Dose and temporal evaluation of ethylene oxide-
induced mutagenicity in the lungs of male big blue mice following
inhalation exposure to carcinogenic concentrations. Environmental and
Molecular Mutagenesis, 58(3), 122–134.
Müller, L. and Gocke, E. (2009) Considerations regarding a permitted daily
exposure calculation for ethyl methanesulfonate. Toxicology Letters,
190(3), 330–332.
Norppa, H., Bonassi, S., Hansteen, I.L., Hagmar, L., Strömberg, U.,
Rössner, P., Boffetta, P., Lindholm, C., Gundy, S., Lazutka, J., Cebulska-
Wasilewska, A., Fabiánová, E., Srám, R.J., Knudsen, L.E., Barale, R. and
Fucic, A. (2006) Chromosomal aberrations and SCEs as biomarkers of
cancer risk. Mutation Research, 600(1–2), 37–45.
Parsons, B.L., Manjanatha, M.G., Myers, M.B., McKim, K.L., Shelton, S.D.,
Wang, Y., Gollapudi, B.B., Moore, N.P., Haber, L.T. and Moore, M.M.
(2013) Temporal changes in K-ras mutant fraction in lung tissue of big
blue B6C3F1 mice exposed to ethylene oxide. Toxicological Sciences,
136(1), 26–38.
Philippin, G., Cadet, J., Gasparutto, D., Mazon, G. and Fuchs, R.P. (2014)
Ethylene oxide and propylene oxide derived N7-alkylguanine adducts
are bypassed accurately in vivo. DNA Repair (Amst), 22, 133–136.
Piegorsch, W.W. and Haseman, J.K. (1991) Statistical methods for analyz-
ing developmental toxicity data. Teratogenesis, Carcinogenesis, and
Mutagenesis, 11, 115–133.
Pottenger, L.H., Bus, J.S. and Gollapudi, B.B. (2007) Genetic toxicity
assessment: employing the best science for human safety evaluation
part VI: when salt and sugar and vegetables are positive, how can gen-
otoxicity data serve to inform risk assessment? Toxicological Sciences,
98(2), 327–331.
Pottenger, L.H. and Gollapudi, B.B. (2009) A case for a new paradigm in
genetic toxicology testing. Mutation Research, 678(2), 148–151.
Pottenger, L.H. and Gollapudi, B.B. (2010) Genotoxicity testing: moving
beyond qualitative “screen and bin” approach towards characterization
of dose–response and thresholds. Environmental and Molecular Muta-
genesis, 51(8–9), 792–799.
Preston, R.J. and Abernethy, D.J. (1993) Studies on the induction of chro-
mosomal aberration and sister chromatid exchange in rats exposed to
styrene by inhalation. IARC Scientific Publications, 127, 225–233.
Recio, L., Donner, M., Abernethy, D., Pluta, L., Steen, A.M., Wong, B.A.,
James, A. and Preston, R.J. (2004) In vivo mutagenicity and mutation
spectrum in the bone marrow and testes of B6C3F1 lacI transgenic
mice following inhalation exposure to ethylene oxide. Mutagenesis, 19,
215–222.
Rhomberg, L., Dellarco, V.L., Siegel-Scott, C., Dearfield, L.K. and Jacobson-
Kram, D. (1990) Quantitative estimation of the genetic risk associated
with the induction of heritable translocations at low-dose exposure:
ethylene oxide as an example. Environmental and Molecular Mutagene-
sis, 16, 104–125.
Ribeiro, L.R., Tabello-Gay, M.N., Salvadori, D.M., Pereira, C.A. and
Becak, W. (1987) Cytogenetic effects of inhaled ethylene oxide in
somatic and germ cells of mice. Archives of Toxicology, 59, 332–335.
Rusyn, I., Asakura, S., Li, Y., Kosyk, O., Koc, H., Nakamura, J., Upton, P.B.
and Swenberg, J.A. (2005) Effects of ethylene oxide and ethylene
inhalation on DNA adducts, apurinic/apyrimidinic sites and expression
of base excision DNA repair genes in rat brain, spleen, and liver. DNA
Repair, 4, 1099–1110.
Segerbäck, D. (1990) Reaction products in hemoglobin and DNA after
in vitro treatment with ethylene oxide and N-(2-hydroxyethyl)-N-
nitrosourea. Carcinogenesis, 11(2), 307–312.
Sisk, S.C., Pluta, L.J., Meyer, K.G., Wong, B.C. and Recio, L. (1997) Assess-
ment of the in vivo mutagenicity of ethylene oxide in the tissues of
B6C3F1 lacI transgenic mice following inhalation exposure. Mutation
Research, 391, 153–164.
Slob, W. (2017) A general theory of effect size, and its consequences for
defining the benchmark response (BMR) for continuous endpoints.
Critical Reviews in Toxicology, 47(4), 342–351.
Slob, W., Moerbeek, M., Rauniomaa, E. and Piersma, A.H. (2005) A statisti-
cal evaluation of toxicity study designs for the estimation of the bench-
mark dose in continuous endpoints. Toxicological Sciences, 84, 167–185.
Steenland, K., Stayner, L. and Deddens, J. (2004) Mortality analyses in a
cohort of 18 235 ethylene oxide exposed workers: follow up extended
from 1987 to 1998. Occupational and Environmental Medicine, 61, 2–7.
Steenland, K., Whelan, E., Deddens, J., Stayner, L. and Ward, E. (2003) Eth-
ylene oxide and breast cancer incidence in a cohort study of 7576
women (United States). Cancer Causes & Control, 14, 531–539.
Stout, J.T. and Caskey, C.T. (1985) HPRT: gene structure, expression, and
mutation. Annual Review of Genetics, 19, 127–148.
Strekalova, E.Y., Chirkova, E.M. and Golubovich, E. (1971) Mutagenic
action of ethylene oxide on sex and somatic cells in male white rats.
Toksikol Nov Prom Khim Veshchestv, 14, 11–16.
Tates, A.D., van Dam, F.J., Natarajan, A.T., van Teylingen, C.M.M., de
Zwart, F.A., Zwinderman, A.H., van Sittert, N.J., Nilsen, A., Nilsern, O.
G., Zahlsen, K., Magnusson, A.L. and Törnqvist, M. (1999) Measure-
ment of HPRT mutations in splenic lymphocytes and haemoglobin
adducts in erythrocytes of Lewis rats exposed to ethylene oxide.
Mutation Research, 431, 397–415.
Texas Commission on Environmental Quality (TCEQ). (2020). Ethylene Oxide
Carcinogenic Dose-Response Assessment. CAS Registry Number: 75-21-8.
Development Support Document. Final, May 15, 2020. Houston, Texas:
Texas Commission on Environmental Quality.
Tompkins, E.M., McLuckie, K.I., Jones, D.J., Farmer, P.B. and Brown, K.
(2009) Mutagenicity of DNA adducts derived from ethylene oxide
exposure in the pSP189 shuttle vector replicated in human Ad293
cells. Mutation Research, 678(2), 129–137.
Törnqvist, M.A., Almberg, J.G., Bergmark, E.N., Nilsson, S. and Osterman-
Golkar, S.M. (1989) Ethylene oxide doses in ethene-exposed fruit store
workers. Scandinavian Journal of Work, Environment & Health, 15,
436–438.
GOLLAPUDI ET AL. 19
U.S. Environmental Protection Agency (U.S. EPA). (1991) Guidelines for
Developmental Toxicity Risk Assessment. EPA/600/FR-91/001. Risk
Assessment Forum. Washington, DC: U.S. Environmental Protection
Agency.
U.S. Environmental Protection Agency (U.S. EPA). (1996) Soil Screening
Guidance. Technical Background Document. Appendix B: Route-to-Route
Extrapolation of Inhalation Benchmarks. EPA/540/R-96/018. Office of
Emergency and Remedial Response. Washington, DC: U.S. Environmen-
tal Protection Agency.
U.S. Environmental Protection Agency (U.S. EPA). (2016). Evaluation of
inhalation carcinogenicity of ethylene oxide. EPA/635/R-16/350Fa.
National Center for Environmental Assessment. Office of Research
and Development. Washington, DC: U.S. Environmental Protection
Agency.
U.S. Environmental Protection Agency (US EPA). (2014) Guidance for
Applying Quantitative Data to Develop Data-Derived Extrapolation Fac-
tors for Interspecies and Intraspecies Extrapolation. EPA/R-14/002F.
Washington, DC: Office of the Science Advisor. Risk Assessment
Forum. U.S. Environmental Protection Agency.
van Sittert, N.J., Boogaard, P.J., Natarajan, A.T., Tates, A.D., Ehrenberg, L.
G. and Törnqvist, M. (2000) Formation of DNA adducts and induction
of mutagenic effects in rats following 4 weeks inhalation exposure to
ethylene oxide as a basis for cancer risk assessment. Mutation
Research, 447, 27–48.
Vergnes, J.S. and Pritts, I.M. (1994) Effects of ethylene on micronucleus
formation in the bone marrow of rats and mice following four week of
inhalation exposure. Mutation Research, 324, 87–91.
Walker, V.E., Sisk, S.C., Upton, P.B., Wong, B.A. and Recio, L. (1997) In vivo
mutagenicity of ethylene oxide at the hprt locus in T-lymphocytes of
B6C3F1 lacI transgenic mice following inhalation exposure. Mutation
Research, 392, 211–222.
Walker, V.E., Wu, K.Y., Upton, P.B., Ranasinghe, A., Scheller, N., Cho, M.H.,
Vergnes, J.S., Skopek, T.R. and Swenberg, J.A. (2000) Biomarkers of
exposure and effect as indicators of potential carcinogenic risk arising
from in vivo metabolism of ethylene to ethylene oxide. Carcinogenesis,
21(9), 1661–1669.
Waters, M.D., Stack, H.F. and Jackson, M.A. (1999) Genetic toxicology
data in the evaluation of potential human environmental carcinogens.
Mutation Research, 437, 21–49.
White, P.A., Long, A.S. and Johnson, G.E. (2020) Quantitative interpreta-
tion of genetic toxicity dose-response data for risk assessment and
regulatory decision-making: current status and emerging priorities.
Environmental and Molecular Mutagenesis, 61(1), 66–83.
Zeller, A., Duran-Pacheco, G. and Guerard, M. (2017) An appraisal of criti-
cal effect sizes for the benchmark dose approach to assess dose–
response relationships in genetic toxicology. Archives of Toxicology, 91
(12), 3799–3807.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Gollapudi BB, Su S, Li AA,
Johnson GE, Reiss R, Albertini RJ. Genotoxicity as a
toxicologically relevant endpoint to inform risk assessment: A
case study with ethylene oxide. Environ Mol Mutagen. 2020;
1–20. https://doi.org/10.1002/em.22408
20 GOLLAPUDI ET AL.
